Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection - PubMed (original) (raw)
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection
Janis V Giorgi et al. J Acquir Immune Defic Syndr. 2002.
Abstract
Laboratory markers that predict HIV-1 disease progression include plasma viral burden, CD4+ T-cell count, and CD38 expression on CD8 T cells. To better understand whether the predictive value of these markers is dependent on how long an individual has been infected, we analyzed data from the Multicenter AIDS Cohort Study early (median = 2.8 years) and late (median = 8.7 years) in the course of infection. Overall, we found that HIV RNA and CD38 levels were similarly predictive of AIDS early on compared with a relatively weaker CD4 cell count signal. Later in the course of infection, CD38 level remained the strongest predictive marker and CD4 cell count registered a marked increase in prognostic power. Among untreated individuals, there was little difference in prognosis (median time to AIDS) associated with given marker values regardless of infection duration. The prognosis given a specific viral load level tended to deteriorate late in the course of infection among those undergoing treatment with monotherapy or combination therapy, however. These data provide a unique historical look at the predictive value and prognostic significance of HIV-1 disease markers at different stages of infection in a large cohort, with direct relevance to current patients who are untreated or for whom treatment is ineffective.
Similar articles
- CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.
Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. Liu Z, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):332-40. doi: 10.1097/00042560-199808010-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9704938 - HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, Johnson M, Gottle R, Devers J, Lederman HM, Bollinger RC. Lubaki NM, et al. J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):19-30. doi: 10.1097/00042560-199909010-00003. J Acquir Immune Defic Syndr. 1999. PMID: 10534143 - CD38+CD8+ T cells as a marker of poor response to therapy in HIV-infected individuals.
Vigano A, Saresella M, Villa ML, Ferrante P, Clerici M. Vigano A, et al. Chem Immunol. 2000;75:207-17. doi: 10.1159/000058770. Chem Immunol. 2000. PMID: 10851786 Review. No abstract available. - Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions?
Savarino A, Bottarel F, Malavasi F, Dianzani U. Savarino A, et al. AIDS. 2000 Jun 16;14(9):1079-89. doi: 10.1097/00002030-200006160-00004. AIDS. 2000. PMID: 10894271 Review. No abstract available.
Cited by
- Identification of antibody targets associated with lower HIV viral load and viremic control.
Grant-McAuley W, Morgenlander WR, Ruczinski I, Kammers K, Laeyendecker O, Hudelson SE, Thakar M, Piwowar-Manning E, Clarke W, Breaud A, Ayles H, Bock P, Moore A, Kosloff B, Shanaube K, Meehan SA, van Deventer A, Fidler S, Hayes R, Larman HB, Eshleman SH; HPTN 071 (PopART) Study Team. Grant-McAuley W, et al. PLoS One. 2024 Sep 17;19(9):e0305976. doi: 10.1371/journal.pone.0305976. eCollection 2024. PLoS One. 2024. PMID: 39288118 Free PMC article. Clinical Trial. - Reference values of lymphocyte subsets from healthy Polish adults.
Roszczyk A, Zych M, Sołdacki D, Zagozdzon R, Kniotek MJ. Roszczyk A, et al. Cent Eur J Immunol. 2024;49(1):26-36. doi: 10.5114/ceji.2024.136371. Epub 2024 Mar 22. Cent Eur J Immunol. 2024. PMID: 38812608 Free PMC article. - Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.
Al-Talib M, Dimonte S, Humphreys IR. Al-Talib M, et al. Cell Mol Immunol. 2024 Sep;21(9):982-998. doi: 10.1038/s41423-024-01140-2. Epub 2024 Mar 8. Cell Mol Immunol. 2024. PMID: 38459243 Free PMC article. Review. - Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles.
Moyano A, Ndlovu B, Mbele M, Naidoo K, Khan N, Mann JK, Ndung'u T. Moyano A, et al. PLoS One. 2023 Jun 2;18(6):e0286507. doi: 10.1371/journal.pone.0286507. eCollection 2023. PLoS One. 2023. PMID: 37267224 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- 5-M01-RR00722/RR/NCRR NIH HHS/United States
- UO1-AI-35039/AI/NIAID NIH HHS/United States
- UO1-AI-35040/AI/NIAID NIH HHS/United States
- UO1-AI-35041/AI/NIAID NIH HHS/United States
- UO1-AI-35042/AI/NIAID NIH HHS/United States
- UO1-AI-35043/AI/NIAID NIH HHS/United States
- UO1-AI-37613/AI/NIAID NIH HHS/United States
- UO1-AI-37984/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials